Merck Sharp & Dohme LLC

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

1. Trial

   PHASE3 registered

   Mar 18, 2026

   Non-small Cell Lung Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

   ClinicalTrials.gov · NCT07431827 (opens the source filing in a new tab)

2. Trial

   PHASE3 registered

   Jan 19, 2026

   Cervical Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

   ClinicalTrials.gov · NCT07216703 (opens the source filing in a new tab)

3. Trial

   PHASE2 registered

   Dec 19, 2025

   Malignant Neoplasm · RECRUITING · sponsor: Merck Sharp & Dohme LLC · KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

   ClinicalTrials.gov · NCT07252739 (opens the source filing in a new tab)

4. Trial

   PHASE1 registered

   Apr 23, 2025

   Malignant Neoplasm · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

   ClinicalTrials.gov · NCT06894771 (opens the source filing in a new tab)

5. Trial

   PHASE1/PHASE2 registered

   Apr 15, 2025

   Ovarian Cancer Recurrent · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

   ClinicalTrials.gov · NCT06843447 (opens the source filing in a new tab)

6. Trial

   PHASE2 registered

   Oct 14, 2024

   Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

   ClinicalTrials.gov · NCT06504394 (opens the source filing in a new tab)

7. Trial

   PHASE1/PHASE2 registered

   Sep 20, 2024

   Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

   ClinicalTrials.gov · NCT06469944 (opens the source filing in a new tab)

8. Trial

   PHASE1 registered

   Jul 14, 2024

   Neoplasm Metastasis · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

   ClinicalTrials.gov · NCT06460961 (opens the source filing in a new tab)

9. Trial

   PHASE3 registered

   May 3, 2024

   Gastroesophageal Cancer · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

   ClinicalTrials.gov · NCT06356311 (opens the source filing in a new tab)

10. Trial

    PHASE2 registered

    Apr 10, 2024

    Renal Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

    ClinicalTrials.gov · NCT06307431 (opens the source filing in a new tab)

11. Trial

    PHASE2 registered

    Dec 26, 2023

    Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

    ClinicalTrials.gov · NCT06099782 (opens the source filing in a new tab)

12. Trial

    PHASE1 registered

    Jul 6, 2023

    Metastatic Solid Tumors, Advanced Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

    ClinicalTrials.gov · NCT05853367 (opens the source filing in a new tab)

13. Trial

    PHASE1/PHASE2 registered

    Jun 23, 2023

    Metastatic Urothelial Carcinoma, Urothelial Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

    ClinicalTrials.gov · NCT05845814 (opens the source filing in a new tab)

14. Trial

    PHASE3 registered

    Jun 13, 2023

    Metastatic Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

    ClinicalTrials.gov · NCT06212752 (opens the source filing in a new tab)

15. Trial

    PHASE3 registered

    Feb 14, 2023

    Metastatic Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

    ClinicalTrials.gov · NCT05722015 (opens the source filing in a new tab)

16. Trial

    PHASE3 registered

    Feb 6, 2023

    Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

    ClinicalTrials.gov · NCT05609968 (opens the source filing in a new tab)

17. Trial

    PHASE3 registered

    Jan 19, 2023

    Melanoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

    ClinicalTrials.gov · NCT05665595 (opens the source filing in a new tab)

18. Trial

    PHASE2 registered

    Oct 18, 2022

    Hodgkin Lymphoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

    ClinicalTrials.gov · NCT05508867 (opens the source filing in a new tab)

19. Trial

    PHASE1/PHASE2 registered

    Jul 27, 2022

    Esophageal Squamous Cell Carcinoma (ESCC) · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

    ClinicalTrials.gov · NCT05342636 (opens the source filing in a new tab)

20. Trial

    PHASE3 registered

    Jul 27, 2022

    Carcinoma, Renal Cell · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

    ClinicalTrials.gov · NCT05899049 (opens the source filing in a new tab)

21. Trial

    PHASE2 registered

    Jul 25, 2022

    High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

    ClinicalTrials.gov · NCT05446870 (opens the source filing in a new tab)

22. Trial

    PHASE3 registered

    Jun 14, 2022

    Colorectal Cancer · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

    ClinicalTrials.gov · NCT05600309 (opens the source filing in a new tab)

23. Trial

    PHASE3 registered

    Apr 2, 2022

    Colorectal Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

    ClinicalTrials.gov · NCT05239741 (opens the source filing in a new tab)

24. Trial

    PHASE3 registered

    Mar 15, 2022

    Carcinoma, Renal Cell · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

    ClinicalTrials.gov · NCT05239728 (opens the source filing in a new tab)

25. Trial

    PHASE3 registered

    Feb 3, 2022

    Endometrial Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

    ClinicalTrials.gov · NCT05173987 (opens the source filing in a new tab)

26. Trial

    PHASE2 registered

    Oct 7, 2021

    Classical Hodgkin Lymphoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

    ClinicalTrials.gov · NCT05008224 (opens the source filing in a new tab)

27. Trial

    PHASE1 registered

    Sep 21, 2021

    Advanced or Metastatic Solid Tumors · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

    ClinicalTrials.gov · NCT05017012 (opens the source filing in a new tab)

28. Trial

    PHASE3 registered

    Jul 28, 2021

    Metastatic Esophageal Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

    ClinicalTrials.gov · NCT04949256 (opens the source filing in a new tab)

29. Trial

    PHASE2 registered

    Jun 7, 2021

    Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

    ClinicalTrials.gov · NCT04875195 (opens the source filing in a new tab)

30. Trial

    PHASE3 registered

    May 25, 2021

    Metastatic Hormone-Sensitive Prostate Cancer · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

    ClinicalTrials.gov · NCT04934722 (opens the source filing in a new tab)

31. Trial

    PHASE3 registered

    Jan 10, 2021

    Endometrial Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

    ClinicalTrials.gov · NCT04634877 (opens the source filing in a new tab)

32. Trial

    PHASE3 registered

    Dec 8, 2020

    Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

    ClinicalTrials.gov · NCT04624204 (opens the source filing in a new tab)

33. Trial

    PHASE4 registered

    Oct 27, 2020

    Squamous Cell Carcinoma of Head and Neck · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

    ClinicalTrials.gov · NCT04489888 (opens the source filing in a new tab)

34. Trial

    PHASE3 registered

    Jul 14, 2020

    Malignant Melanoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

    ClinicalTrials.gov · NCT04889118 (opens the source filing in a new tab)

35. Trial

    PHASE3 registered

    Jul 6, 2020

    Lung Neoplasms, Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

    ClinicalTrials.gov · NCT04380636 (opens the source filing in a new tab)

36. Trial

    PHASE1/PHASE2 registered

    Jul 1, 2020

    Melanoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

    ClinicalTrials.gov · NCT04305054 (opens the source filing in a new tab)

37. Trial

    PHASE1/PHASE2 registered

    Jun 26, 2020

    Melanoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

    ClinicalTrials.gov · NCT04303169 (opens the source filing in a new tab)

38. Trial

    PHASE1 registered

    Jun 26, 2020

    Lymphoma, B-Cell · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

    ClinicalTrials.gov · NCT04317066 (opens the source filing in a new tab)

39. Trial

    PHASE3 registered

    May 19, 2020

    Urinary Bladder Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

    ClinicalTrials.gov · NCT04241185 (opens the source filing in a new tab)

40. Trial

    PHASE2 registered

    Mar 4, 2020

    Head and Neck Squamous Cell Carcinoma (HNSCC) · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

    ClinicalTrials.gov · NCT04220866 (opens the source filing in a new tab)

41. Trial

    PHASE3 registered

    Feb 28, 2020

    Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC) · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

    ClinicalTrials.gov · NCT04210115 (opens the source filing in a new tab)

42. Trial

    PHASE1/PHASE2 registered

    Dec 19, 2019

    Carcinoma, Non-Small-Cell Lung · RECRUITING · sponsor: Merck Sharp & Dohme LLC · KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    ClinicalTrials.gov · NCT04165070 (opens the source filing in a new tab)

43. Trial

    PHASE2 registered

    Dec 19, 2019

    Carcinoma, Non-Small-Cell Lung · COMPLETED · sponsor: Merck Sharp & Dohme LLC · KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

    ClinicalTrials.gov · NCT04165083 (opens the source filing in a new tab)

44. Trial

    PHASE1 registered

    Dec 9, 2019

    Mesothelioma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

    ClinicalTrials.gov · NCT04153565 (opens the source filing in a new tab)

45. Trial

    PHASE2 registered

    Nov 18, 2019

    Solid Tumors · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

    ClinicalTrials.gov · NCT04123366 (opens the source filing in a new tab)

46. Trial

    PHASE3 registered

    Oct 22, 2019

    Endometrial Neoplasms · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

    ClinicalTrials.gov · NCT04865289 (opens the source filing in a new tab)

47. Trial

    PHASE3 registered

    Apr 1, 2019

    Carcinoma, Squamous Cell · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

    ClinicalTrials.gov · NCT03833167 (opens the source filing in a new tab)

48. Trial

    PHASE3 registered

    Dec 27, 2018

    Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

    ClinicalTrials.gov · NCT03725059 (opens the source filing in a new tab)

49. Trial

    PHASE2 registered

    Oct 19, 2018

    Non-small Cell Lung Cancer · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

    ClinicalTrials.gov · NCT03631784 (opens the source filing in a new tab)

50. Trial

    PHASE2 registered

    Apr 9, 2018

    Hodgkin Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

    ClinicalTrials.gov · NCT03407144 (opens the source filing in a new tab)

51. Trial

    PHASE3 registered

    Apr 27, 2017

    Carcinoma, Hepatocellular · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

    ClinicalTrials.gov · NCT03062358 (opens the source filing in a new tab)

52. Trial

    PHASE3 registered

    Mar 7, 2017

    Triple Negative Breast Neoplasms · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

    ClinicalTrials.gov · NCT03036488 (opens the source filing in a new tab)

53. Trial

    PHASE2 registered

    Dec 18, 2015

    Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

    ClinicalTrials.gov · NCT02628067 (opens the source filing in a new tab)

54. Trial

    PHASE3 registered

    Nov 6, 2015

    Non-small Cell Lung Cancer · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

    ClinicalTrials.gov · NCT02504372 (opens the source filing in a new tab)

55. Trial

    PHASE3 registered

    Jul 16, 2015

    Melanoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

    ClinicalTrials.gov · NCT02362594 (opens the source filing in a new tab)

56. Trial

    PHASE1/PHASE2 registered

    Mar 19, 2015

    Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    ClinicalTrials.gov · NCT02332668 (opens the source filing in a new tab)